Tag: Cancer: Lymphoma
Bayer to Pay $10 Billion to Settle Roundup Lawsuits
Amount includes $1.25 billion for potential future claims from people who used Roundup
Rituximab + Chemo Ups Survival in Pediatric B-Cell Non-Hodgkin Lymphoma
Event-free survival significantly longer for children, teens with high-grade, high-risk disease
Outcomes Equal for AYA Hodgkin Therapy at Peds, Adult Centers
Treatment strategies differ, but outcomes equivalent among adolescent, young adult Hodgkin patients
Whole-Body DW MRI Can Help Assess Pediatric Tumor Response
Good agreement for treatment response assessments with DW MRI, FDG PET seen in children, young adults
Low Muscle Mass, Density Linked to Shorter Survival in Lymphoma
13 percent of DLBCL patients had LMM, LMD, which was associated with shorter OS and PFS
Recommendations Issued for R/R Pediatric Hodgkin Lymphoma
Recommendations developed for salvage therapy for pediatric patients with first relapse/refractory cHL
Thoracic Radiation May Increase Fatigue, Dyspnea in Short Term
In patients with lung cancer or lymphoma, increase in heart dose tied to decrease in physical activity
Nitrite Consumption May Up Risk for Non-Hodgkin Lymphoma
Nitrite intake linked to carcinogenicity leading to NHL, development of diffuse large B cell lymphoma
Survival Worse for Nonwhite Children With Hodgkin Lymphoma
Risk for postrelapse mortality 2.7-, 3.5-fold higher for Hispanics, non-Hispanic blacks versus whites
ASH: AlloHSCT Feasible After PD-1, PD-L1 mAb in Hodgkin Lymphoma
Outcomes good for those treated with a PD-1 or PD-L1 inhibitor before undergoing allogeneic HSCT
